Mr. Sebastien Plouffe reports

DEFENCE'S ACCUM TECHNOLOGY WITH ADC AND RADIOPHARMACEUTICAL PROGRAMS TARGET CANCER

Defence Therapeutics Inc.'s highly impactful programs on ADC (antibody-drug conjugate) and radiopharma programs, which includes collaborations and preclinical studies on cancer therapies with Accum, are continuing.

Defence's Accum-based ADCs have demonstrated enhanced intracellular delivery and cytotoxic activity in multiple preclinical cancer models compared with conventional ADCs. Defence continues to advance studies that validate additional Accum-based ADCs, including optimization to increase the value and to attract pharmaceutical and biotechnology companies for potential licensing deals and co-development opportunities. In addition, collaborations and preclinical studies with ADC companies are continuing to validate and confirm the significant efficacy improvement when Defence's Accum technology is added to their respective ADCs.

Defence's radiopharma-focused program continues to enhance the optimization of Accum radiolabelling with studies performed by the Canadian Nuclear Laboratories (CNL) under, notably, the CNRI-H program that Defence was granted. The complete study is being performed, including biodistribution, pharmacokinetic profile and therapeutic potency, using radiolabelled Accum with selected antibodies. Defence's scientific team is confident that the addition of the Accum technology being applied in the radiopharmaceuticals industry may be transformative.

The global ADC market size is projected to grow from $13.51-billion (U.S.) in 2025 to $29.9-billion (U.S.) by 2034 at a compound annual growth rate (CAGR) of 9.23 per cent from 2024 to 2034. The global radiopharmaceutical market is projected to reach $16.87-billion (U.S.) by 2033, growing at a CAGR of 9.9 per cent during the forecast period (2025 to 2033).

Defence's Accum technology optimization is also currently continuing, with more detail to be released upon completion of all the studies related.

The company will announce key results when they become available and completed as well as details on partnerships when and if deals and licensing occurred. Defence continues to work on studies in Canada, mainly at Defence's laboratory located in Montreal, Canada, and, in parallel, the company continues pursuing its plan to expand its presence to the United States.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded clinical-stage biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the Accum technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.

We seek Safe Harbor.